California's new proposed psychedelics "decriminalization" would, in fact, LEGALIZE possession of many psychedelic substances.
California's new proposed psychedelics "decriminalization" would, in fact, LEGALIZE possession of many psychedelic substances.
MINDCURE's R&D on traumatic brain injury (TBI) targets the LARGEST individual market for psychedelic drugs.
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
MINDCURE's first line of mushroom-based nootropics now available for sale.
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
MINDCURE adds bioinformatics to its drug development platform.
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
MindMed inks a new partnership for drug development and expands its pipeline.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now